Patents Assigned to MicroBioMed Corporation
  • Patent number: 6251302
    Abstract: The present invention provides, a 3 or 4-amino-1,8-naphthalimide compound having polyether substituent groups at the 3 or 4-position and the imide position. The polyether groups are linked to a hydrocarbon directly linked at the 3 or 4-amino position and the imide position. The polyether groups render the 3 or 4-amino-1,8-naphthalimide compound sufficiently soluble in a fluid such that visualization of the fluid by color or fluoresence is allowed. In one advantageous embodiment, the 3 or 4-amino-1,8-naphthalimide is obtained from the mixture of 4-chloro-1,8-naphthalic anhydride with monoamine polyether.
    Type: Grant
    Filed: January 15, 1998
    Date of Patent: June 26, 2001
    Assignee: MicroBioMed Corporation
    Inventors: Ronald E. Utecht, David E. Lewis
  • Patent number: 5917045
    Abstract: A class of predominantly hydrophilic 1,8-naphthalimide dyes. The dye contains at least two 1,8-naphthalimide ring systems, joined by a spacer moiety. Each of the 1,8-naphthalimide ring system has a ring nitrogen atom and bears, at the 4 position, an amino nitrogen atom, carrying a hydrogen. The remaining unsatisfied valences, if present, of the ring nitrogen atoms or the amino nitrogen atoms, or all, are occupied by one or more alkyl substituents. Each of the 1,8-naphthalimide ring system is free of an azo substituent and is also free of a nucleofuge. Upon activation by an activating agent in an environment independent of the presence or absence of oxygen, these compounds generate activated species. The activated species can cause structural changes in lipid and any associated proteins and polypeptides, extra- or intra-cellular or transmembrane, leading to polymerization and crosslinking.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 29, 1999
    Assignee: MicroBioMed Corporation
    Inventors: David E. Lewis, Ronald E. Utecht, Millard M. Judy, J. Lester Matthews
  • Patent number: 5766600
    Abstract: A class of predominantly hydrophobic non-azo N-substituted 1,8-naphthalimide compounds, each bearing, at its 3-position, a nucleofuge and, at its 4-position, a heteroatomic electron-releasing group. The heteroatomic electron-releasing group is being characterized as having a heteroatom directly linked to the 4-position of the ring, and having at least one hydrogen directly attached to the heteroatom. Upon activation by an activating agent in an environment independent of the presence or absence of oxygen, these compounds generate activated species. The activated species initiate chemical changes in lipid bilayer membranes of viruses and other target cells. These changes can eradicate viruses and other target cells. The activated species can also cause structural changes in lipid and any associated proteins and polypeptides at a level beneath the surface of the membrane, leading to polymerization and crosslinking.
    Type: Grant
    Filed: May 3, 1995
    Date of Patent: June 16, 1998
    Assignee: MicroBioMed Corporation
    Inventors: David E. Lewis, Ronald E. Utecht, Millard M. Judy, J. Lester Matthews
  • Patent number: 5565551
    Abstract: A class of predominantly hydrophobic non-azo N-substituted 1,8-naphthalimide compounds, each bearing, at its 3-position, a nucleofuge and, at its 4-position, a heteroatomic electron-releasing group. The heteroatomic electron-releasing group is being characterized as having a heteroatom directly linked to the 4-position of the ring, and having at least one hydrogen directly attached to the heteroatom. Upon activation by an activating agent in an environment independent of the presence or absence of oxygen, these compounds generate activated species. The activated species initiate chemical changes in lipid bilayer membranes of viruses and other target cells. These changes can eradicate viruses and other target cells. The activated species can also cause structural changes in lipid and any associated proteins and polypeptides at a level beneath the surface of the membrane, leading to polymerization and crosslinking.
    Type: Grant
    Filed: May 3, 1995
    Date of Patent: October 15, 1996
    Assignee: MicroBioMed Corporation
    Inventors: David E. Lewis, Ronald E. Utecht, Millard M. Judy, J. Lester Matthews
  • Patent number: 5420136
    Abstract: A class of predominantly hydrophobic non-azo N-substituted 1,8-naphthalimide compounds, each bearing, at its 3-position, a nucleofuge and, at its 4-position, a heteroatomic electron-releasing group. The heteroatomic electron-releasing group is being characterized as having a heteroatom directly linked to the 4-position of the ring, and having at least one hydrogen directly attached to the heteroatom. Upon activation by an activating agent in an environment independent of the presence or absence of oxygen, these compounds generate activated species. The activated species initiate chemical changes in lipid bilayer membranes of viruses and other target cells. These changes can eradicate viruses and other target cells. The activated species can also cause structural changes in lipid and any associated proteins and polypeptides at a level beneath the surface of the membrane, leading to polymerization and crosslinking.
    Type: Grant
    Filed: August 9, 1993
    Date of Patent: May 30, 1995
    Assignee: MicroBioMed Corporation
    Inventors: David E. Lewis, Ronald E. Utecht, Millard M. Judy, J. Lester Matthews
  • Patent number: 5407071
    Abstract: A package for an elongated flexible fiber. The package comprises a pair of package portions which define a fiber receiving cavity therein. Lips around the perimeter of the package allow a fiber to be wrapped thereon and passed between the lips into the fiber receiving cavity. Each package portion defines a fiber end receiving cavity therein, each fiber end receiving cavity being adapted for receiving an end of the fiber. Each fiber receiving cavity may be deflected away from the opposite package portion, thereby freeing the corresponding end of the fiber. The natural spring action of the elastically flexible fiber will cause the end of the fiber to pop radially outwardly from the package. Terminals, operating tips and other devices may be attached to the ends of the fibers.
    Type: Grant
    Filed: August 9, 1993
    Date of Patent: April 18, 1995
    Assignees: MyriadLase, Inc., MicroBioMed Corporation
    Inventors: Harvey A. Lawhon, William W. Gardetto
  • Patent number: 5263585
    Abstract: A package for an elongated flexible fiber. The package comprises a pair of package portions which define a fiber receiving cavity therein. Lips around the perimeter of the package allow a fiber to be wrapped thereon and passed between the lips into the fiber receiving cavity. Each package portion defines a fiber end receiving cavity therein, each fiber end receiving cavity being adapted for receiving an end of the fiber. Each fiber receiving cavity may be deflected away from the opposite package portion, thereby freeing the corresponding end of the fiber. The natural spring action of the elastically flexible fiber will cause the end of the fiber to pop radially outwardly from the package. Terminals, operating tips and other devices may be attached to the ends of the fibers.
    Type: Grant
    Filed: May 7, 1992
    Date of Patent: November 23, 1993
    Assignees: MyriadLase, Inc., MicroBioMed Corporation
    Inventors: Harvey A. Lawhon, William W. Gardetto
  • Patent number: 5235045
    Abstract: A class of predominantly hydrophobic non-azo N-substituted 1,8-naphthalimide compounds, each bearing, at its 3-position, a nucleofuge and, at its 4-position, a heteroatomic electron-releasing group. The heteroatomic electron-releasing group is being characterized as having a heteroatom directly linked to the 4-position of the ring, and having at least one hydrogen directly attached to the heteroatom. Upon activation by an activating agent in an environment independent of the presence or absence of oxygen, these compounds generate activated species. The activated species initiate chemical changes in lipid bilayer membranes of viruses and other target cells. These changes can eradicate viruses and other target cells. The activated species can also cause structural changes in lipid and any associated proteins and polypeptides at a level beneath the surface of the membrane, leading to polymerization and crosslinking.
    Type: Grant
    Filed: March 19, 1992
    Date of Patent: August 10, 1993
    Assignee: MicroBioMed Corporation
    Inventors: David E. Lewis, Ronald E. Utecht, Millard M. Judy, J. Lester Matthews